| Identification | Back Directory | [Name]
3-Thiazolidineacetamide, 5-[1-[3-fluoro-5-methoxy-4-(1H-1,2,4-triazol-5-ylmethoxy)phenyl]ethylidene]-N,N-dimethyl-4-oxo-2-thioxo-, (5Z)- | [CAS]
2503017-11-4 | [Synonyms]
NADI-351
3-Thiazolidineacetamide, 5-[1-[3-fluoro-5-methoxy-4-(1H-1,2,4-triazol-5-ylmethoxy)phenyl]ethylidene]-N,N-dimethyl-4-oxo-2-thioxo-, (5Z)- | [Molecular Formula]
C19H20FN5O4S2 | [MOL File]
2503017-11-4.mol | [Molecular Weight]
465.52 |
| Hazard Information | Back Directory | [Uses]
NADI-351 is an orally active and potent Notch1 inhibitor that selectively disrupts Notch1 transcription complexes and reduces Notch1 recruitment to target genes. NADI-351 can be utilized in cancer research[1]. | [References]
[1] Alvarez-Trotta A, et al. Pharmacological Disruption of the Notch1 Transcriptional Complex Inhibits Tumor Growth by Selectively Targeting Cancer Stem Cells. Cancer Res. 2021 Jun 15;81(12):3347-3357. DOI:10.1158/0008-5472.CAN-20-3611 |
|
|